New award for vital research into the causes of birth defects

20 Jul 2018, 3:06 p.m.

Neural tube imaging - Gabriel Galea

Dr Gabriel Galea has been awarded a Wellcome Trust Clinical Research Career Development Fellowship to continue important research into the molecules, genes and physical forces that control the formation of the neural tube in the developing embryo.The neural tube, which is the structure that eventually develops into the brain and spinal cord, normally closes while a baby is still developing in the womb. Faulty neural tube closure causes conditions like spina bifida – a severe birth defect where there is a gap in the spine and the spinal cord is exposed. Spina bifida patients are often incapable of walking, and may require operations to drain fluid from the brain later in life.

Failures of neural tube closure continue to affect 1 in 1000 pregnancies in the UK. The eventual aim of the research is therefore to predict and ultimately prevent these serious conditions.

Dr Galea, who is currently a Wellcome Trust fellow at the UCL Great Ormond Street Institute of Child Health (ICH) will lead new research examining the mechanical forces involved in the formation of the body’s organs, including the brain and spinal cord, while the embryo is still developing in the womb.

The team will use cutting edge imaging methods and laser technology to manipulate individual cells in developing mouse embryos to gain a better understanding of the physical forces at play during normal neural tube closure, and how these go wrong in embryos which develop spina bifida.

Following on from previous research where Dr Galea’s team identified a new embryonic tissue structure specifically involved in closing the neural tube in the lower part of the spine, the new study will also explore whether spina bifida in the upper parts of the spine results from different neural tube closure defects.

The study will be carried out at the Newlife Birth Defects Centre at ICH, the research partner of Great Ormond Street Hospital (GOSH) in collaboration with GOSH/ICH researchers Professors Andy Copp and Nicholas Greene.

Spotlight on our Research Co-ordinators

Meet the staff who keep clinical trials on track, ensure the data is up-to-date, that rules are followed and families get their agreed upon support.

Better understanding leukaemia for children with down syndrome

Researchers have mapped the evolution of a type of leukaemia that is exclusive to children with Down syndrome and may have identified an overarching weakness in the cancer's genetic makeup.

Gentler treatment eliminates early deaths for children with relapsed leukaemia

A groundbreaking national study led by clinicians at Great Ormond Street Hospital (GOSH) has shown that children and young people with relapsed acute lymphoblastic leukaemia (ALL) can be treated safely with significantly less intensive chemotherapy.

NHS eye gene therapy restores Saffie's sight

Saffie has had her sight restored thanks to life-changing eye gene therapy for rare blindness at GOSH